DNA修复基因ERCC4 rs6498486、ERCC5 rs751402多态性与唾液腺肿瘤发病风险的关系

上海口腔医学 ›› 2013, Vol. 22 ›› Issue (4): 438-442.

DNA修复基因ERCC4 rs6498486、ERCC5 rs751402多态性与唾液腺肿瘤发病风险的关系

孟雪，王秋旭，陈莫耶，秦刚，王宇鹏，刘维贤

(中国医科大学附属盛京医院口腔颌面外科，辽宁沈阳 110004)

收稿日期:2012-12-21 修回日期:2013-01-24 出版日期:2013-08-10 发布日期:2013-08-10
通讯作者: 刘维贤，E-mail: liuwx@sj-hospital.org
作者简介:孟雪(1986-)，女，硕士，E-mail:cmumengxue@126.com

DNA repair gene polymorphisms in ERCC4 rs6498486 and ERCC5 rs751402 and risk of salivary gland tumors

MENG Xue, WANG Qiu-xu, CHEN Mo-ye, QIN Gang, WANG Yu-peng, LIU Wei-xian

Department of Oral and Maxillofacial Surgery, Shengjing Hospital, China Medical University. Shenyang 110004, Liaoning Province, China

Received:2012-12-21 Revised:2013-01-24 Online:2013-08-10 Published:2013-08-10

摘要/Abstract

摘要： 目的：探讨DNA修复基因ERCC4、ERCC5多态性与唾液腺肿瘤发病风险的关系。方法：采用病例-对照研究方法，应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对133例经组织学确诊的唾液腺肿瘤病例和142例按年龄、性别匹配的健康对照组的ERCC4 rs6498486与ERCC5 rs751402 2个多态基因型进行检测，应用SPSS 18.0软件包中的多因素Logistic回归分析进行基因多态性与唾液腺肿瘤发病风险关系评估。结果：与(CC+CT)型相比，ERCC5 rs751402多态纯合TT型携带者唾液腺肿瘤发病风险降低(OR=0.45，95% CI：0.21，0.98)，差异具有显著性(P<0.05)。唾液腺肿瘤病例组与对照组间ERCC4 rs6498486多态基因型频率分布无显著差异(P>0.05)。结论：携带ERCC5 rs751402多态TT型个体唾液腺肿瘤的发病风险可能降低。

关键词: 唾液腺肿瘤, 单核苷酸多态性, 切除修复交叉互补基因4, 切除修复交叉互补基因5

Abstract: PURPOSE: To investigate the association between ERCC4 and ERCC5 polymorphisms and risk of salivary gland tumors. METHODS: Case-control study was carried out in 133 cases of histologically confirmed salivary gland tumors and 142 age and gender matched healthy control cases. Polymorphisms of ERCC4 rs6498486 and ERCC5 rs751402 were detected by PCR-RFLP. Multiple factors logistic regression analysis was conducted to investigate the association between gene polymorphisms and risk of salivary gland tumors using SPSS 18.0 software package. RESULTS: The genotype distribution of each polymorphism was found to be of Hardy-Weinberg equilibrium in the study. ERCC5 rs751402 TT genotype was associated with risk of salivary gland tumors (TT vs. CC+CT: OR=0.45, 95% CI: 0.21-0.98, P=0.046). No significant association was found in ERCC4 rs6498486. CONCLUSIONS: The results suggest that ERCC5 rs751402 polymorphism may be associated with risk of salivary gland tumors.

Key words: Salivary gland tumor, Single nucleotide polymorphism, ERCC4, ERCC5

中图分类号:

R739.8

孟雪, 王秋旭, 陈莫耶, 秦刚, 王宇鹏, 刘维贤. DNA修复基因ERCC4 rs6498486、ERCC5 rs751402多态性与唾液腺肿瘤发病风险的关系[J]. 上海口腔医学, 2013, 22(4): 438-442.

MENG Xue, WANG Qiu-xu, CHEN Mo-ye, QIN Gang, WANG Yu-peng, LIU Wei-xian. DNA repair gene polymorphisms in ERCC4 rs6498486 and ERCC5 rs751402 and risk of salivary gland tumors[J]. Shanghai Journal of Stomatology, 2013, 22(4): 438-442.

参考文献

[1] 中华口腔医学会口腔颌面外科专业委员会唾液腺疾病学组, 中国抗癌协会头颈肿瘤外科专业委员会唾液腺肿瘤协作组. 涎腺肿瘤的诊断和治疗指南[J]. 中华口腔医学杂志,2010,45(3): 131-134.
[2] Liu W, Zhu E, Wang R, et al. Cyclin D1 gene polymorphism, A870G, is associated with an increased risk of salivary gland tumors in the Chinese population[J]. Cancer Epidemiol,2011,35(4): e12-17.
[3] Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours[J]. Ear Nose Throat J, 2006, 85(2): 74.
[4] 张相民, 蓝小林, 朱小燕. 腮腺复发性多形性腺瘤的再手术治疗及疗效观察[J]. 临床耳鼻咽喉头颈外科杂志, 2011, 25(19): 905-906.
[5] Wang JM, Xu B, Hsieh CC, et a1. Longitudinal trends of stomach cancer and esophageal cancer in Yangzhong County: a high-incidence rural area of China[J]. Eur J Gastroenterol Hepatol, 2005, 17(12): 1339-1344.
[6] 陈建国, 陆建华. 国内外癌症防制现状[J]. 肿瘤, 2007, 27(9): 755-759.
[7] 戴俊程, 胡志斌, 陈亦江, 等. 核苷酸切除修复通路基因多态性与肺癌易感性研究[J]. 中国肿瘤外科杂志, 2009,1(5): 285-292.
[8] Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis[J]. Int J Med Sci, 2007, 4(2): 59-71.
[9] Zienolddiny S, Campa D, Lind H , et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer[J]. Carcinogenesis, 2006, 27(3): 560-567.
[10] Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53[J]. Science, 1996, 274(5286): 430-432.
[11] Wood RD. Mammalian nucleotide excision repair proteins and interstrand crosslink repair[J]. Environ Mol Mutagen, 2010, 51(6): 520-526.
[12] Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2011, 17(16): 5513-5522.
[13] Cheng L, Sturgis EM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck[J]. Cancer, 2002, 94(2): 393-397.
[14] Abedin Z, Louis-Juste M, Stangl M, et al. The role of base excision repair genes OGG1, APN1 and APN2 in benzo[a]pyrene-7, 8-dione induced p53 mutagenesis[J]. Mutat Res, 2013, 750(1-2): 121-128.
[15] Nelson HH, Christensen B, Karagas MR. The XPC poly-AT polymorphism in non-melanoma skin cancer[J]. Cancer Lett, 2005, 222(2): 205-209.
[16] Araújo SJ, Nigg EA, Wood RD. Strong functional interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome[J]. Mol Cell Biol, 2001, 21(7): 2281-2291.
[17] Bai J, Guo XG, Bai XP. Epidermal growth factor receptor-related DNA repair and radiation-resistance regulatory mechanisms: a mini-review[J]. Asian Pac J Cancer Prev, 2012, 13(10): 4879-4881.
[18] 金文胜, 潘长玉. 国际糖尿病联盟关于代谢综合征定义的全球共识[J]. 中华内分泌代谢杂志, 2005, 21(4): 附录4b-1-附录4b-2.
[19] 宋姗爱, 梁军, 姜韬, 等. XPG基因多态性与奥沙利铂对晚期胃癌疗效的相关性[J]. 齐鲁医学杂志, 2010, 25(2): 98-100.
[20] 温树信, 唐平章, 张雪梅, 等. 着色性干皮病G组基因多态性与喉癌和喉咽癌风险的相关性[J]. 中国医学科学院学报, 2006, 28(5): 703-706.
[21] Le Morvan V, Longy M, Bona?ti-Pelli??C, et al. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients[J]. Int J Cancer, 2006, 119(7): 1732-1735.
[22] 陈建芳, 梁后杰, 邹岚, 等. ERCC5基因+25A>G多态性与晚期结直肠癌铂类药物疗效的相关性[J]. 临床肿瘤学杂志, 2011, 16(1): 9-13.
[23] He C, Duan Z, Li P, et al. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer[J]. Anticancer Drugs,2013,24(3): 300-305.
[24] Crawford EL, Blomquist T, Mullins DN, et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2FI/YYI interactions[J]. Carcinogenesis, 2007, 28(12): 2552-2559.